[Insight] Dongkook Pharmaceutical Nears W1 Trillion Revenue as Centellian24 Drives Global Expansion

Dongkook Pharmaceutical is on the verge of reaching a W1 trillion ($700 million) annual revenue mark, driven by the rapid growth of its Centellian24 dermacosmetics brand and solid expansion in pharmaceuticals, health supplements, and international markets. The South Korean company reported a first-half consolidated revenue of W509.9 billion in 2026, a 11.5% increase from the previous year, marking the first time its half-year revenue surpassed W500 billion.

Operating profit climbed 12.6% to W53.4 billion, while net profit rose 20.9% to W43.6 billion. Revenue grew 16.7% to W436.5 billion, with operating profit up 23.4% to W47.8 billion and net profit increasing 32.9% to W40.8 billion. This growth is characterized by more than just scale, as profit growth outpaced revenue growth, with expansion spread across various sectors, including prescription and over-the-counter medicines, health and beauty products, health supplements, and international businesses.

Centellian24 is at the forefront of this global expansion, with overseas sales of the brand soaring 566% year-over-year in the second quarter. The brand has made inroads into major retail channels in the United States, Japan, and Southeast Asia, signaling a shift from traditional export models to mainstream overseas retail presence.

Dongkook Pharmaceutical's expertise in pharmaceuticals is being leveraged to build a consumer healthcare platform, with brands like Madeca21 and Madeca Pharmacia expanding the Madeca identity across different consumer segments and distribution channels. This approach allows the company to capitalize on the growing demand for health functional foods and other consumer healthcare products.

Despite focusing on consumer healthcare, Dongkook Pharmaceutical's core pharmaceutical business continues to grow, with a 10.5% increase in prescription drug sales and a 9.4% rise in over-the-counter sales. The company is also investing in drug delivery systems and next-generation therapies, promising a longer-term growth track for its pharmaceutical division.

Dongkook Pharmaceutical's global ambitions extend beyond Centellian24, as the company has been expanding its pharmaceutical business through licensing and supply partnerships, such as its agreement with FAES FARMA in Spain for Uresco, a combination therapy for benign prostatic hyperplasia. This international expansion strategy demonstrates the company's commitment to building a diversified portfolio of healthcare products and services.